Effect of Graft Source on Unrelated Donor Hemopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia after Reduced-Intensity or Nonmyeloablative Conditioning: A Study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 1059-1067

  Malard, Florent ^a,b   Milpied, Noel ^c   Blaise, Didier ^d   Chevallier, Patrice ^a   Michallet, Mauricette ^e   Lioure, Bruno ^f   Clément, Laurence ^g   Hicheri, Yosr ^h   Cordonnier, Catherine ⁱ   Huynh, Anne ^j   Yakoub Agha, Ibrahim ^k   Peffault de Latour, Regis ^l   Mohty, Mohamad ^b,m  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e UNIVERSITÉ LYON 1   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j Institut Universitaire du Cancer Toulouse Oncopole   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

10 10 Matched unrelated donor; 9 10 Mismatched unrelated donor; Acute myeloid leukemia; Allogeneic stem cell transplantation; Nonmyeloablative conditioning; Reduced intensity conditioning; Umbilical cord blood

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER GROWTH; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; THROMBOCYTE; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; UNRELATED DONORS; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; CHRONIC DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; FRANCE; GENETICS; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MEDICAL SOCIETY; MIDDLE AGED; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SIBLING; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADULT; AGED; CHRONIC DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FRANCE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; RETROSPECTIVE STUDIES; SIBLINGS; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84941317769     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.02.014     Document Type: Article

References (43)

1. Malard F., Chevallier P., Guillaume T., et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. Biol Blood Marrow Transplant 2014, 20:1217-1223.
2. Hahn T., McCarthy P.L., Hassebroek A., et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013, 31:2437-2449.
3. Gragert L., Eapen M., Williams E., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014, 371:339-348.
4. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
5. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
6. Brunstein C.G., Eapen M., Ahn K.W., et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012, 119:5591-5598.
7. Weisdorf D., Eapen M., Ruggeri A., et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a Center for International Blood and Marrow Transplant Research-Eurocord analysis. Biol Blood Marrow Transplant 2014, 20:816-822.
8. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
9. Champlin R., Khouri I., Komblau S., et al. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park) 1999, 13:621-628. discussion 631, 635-638, 641.
10. Mohty M., Malard F., Blaise D., et al. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. Cancer 2015, 121:562-569.
11. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
12. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006, 24:5695-5702.
13. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
14. Ruggeri A., Sanz G., Bittencourt H., et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 2014, 28:779-786.
15. Scaradavou A., Brunstein C.G., Eapen M., et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013, 121:752-758.
16. Mohty M., Jacot W., Faucher C., et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003, 17:2168-2177.
17. Bay J.O., Peffault de Latour R., Bruno B., et al. Diagnosis and treatment of CMV and EBV reactivation as well as post-transplant lymphoproliferative disorders following allogeneic stem cell transplantation: an SFGM-TC report. Pathol Biol (Paris) 2013, 61:152-154.
18. Malard F., Szydlo R.M., Brissot E., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
19. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
20. Flowers M.E., Kansu E., Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999, 13:1091-1112. viii-ix.
21. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
22. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
23. Cahu X., Rialland F., Touzeau C., et al. Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15:1531-1537.
24. Peric Z., Cahu X., Chevallier P., et al. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation. Bone Marrow Transplant 2012, 47:251-257.
25. Malard F., Furst S., Loirat M., et al. Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning. Leukemia 2013, 27:2113-2117.
26. Gallardo D., de la Camara R., Nieto J.B., et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009, 94:1282-1288.
27. Schmitz N., Eapen M., Horowitz M.M., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006, 108:4288-4290.
28. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
29. Mohty M., Labopin M., Balere M.L., et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010, 24:1867-1874.
30. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
31. Walker I., Schultz K.R., Toze C.L., et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. Blood 2014, 124. [Abstract 38].
32. Chen Y.B., Aldridge J., Kim H.T., et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant 2012, 18:805-812.
33. Peffault de Latour R., Brunstein C.G., Porcher R., et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2013, 19:1355-1360.
34. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010, 28:2859-2867.
35. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
36. Chen Y.B., Li S., Lane A.A., et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for patients with Fms-like Tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 2014, 20:2042-2048.
37. Sandmaier B.M., Khaled S.K., Oran B., et al. Results of a phase 1study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell transplantation. Blood 2014, 124. [Abstract 428].
38. Eapen M., Klein J.P., Sanz G.F., et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011, 12:1214-1221.
39. Eapen M., Klein J.P., Ruggeri A., et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 2014, 123:133-140.
40. Malard F., Gagne K., Chevallier P., et al. HLA-A, -B, -C and -DRB1 high resolution matching can improve patient' outcome after double umbilical allogeneic stem cell transplantation (allo-SCT). ASH Annual Meeting Abstracts 2013, 122. [Abstract 414].
41. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
42. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
43. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.